Nasdaq:US$18.06 (-0.03) | HKEX:HK$28.95 (+0.15) | AIM:£2.90 (-0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors